Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
MHLW Orders Updates from Chugai Following Criticism for Reporting Deficiencies by Roche in US
In response to the European Medicines Agency’s (EMA) investigation of F. Hoffmann-La Roche of Switzerland for failing to assess the need to report to regulatory authorities roughly 80,000 safety reports collected in the US, the Ministry of Health, Labor and…
To read the full story
REGULATORY
- Two Bayer/AskBio Gene Therapies Bag Sakigake Designation
December 11, 2025
- Truqap Braced for Price Cut after Cost-Effectiveness Assessment
December 11, 2025
- LDP Lawmakers’ League Urges Continued Coverage for Local Transdermal Analgesics
December 10, 2025
- Senior LDP Lawmakers Call for “Net Plus” in FY2026 Fee, Drug Price Revisions
December 10, 2025
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…